The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
RenBio Announces New Awards for DNA-Based MYO Technology™ Platform for Antiviral Applications
Jul 25, 2024•almost 2 years ago
Contract Type
partnership
New YorkBiotechnologyHealth CareTherapeutics
Description
RenBio announced that it has received funding to evaluate DNA-based delivery of antiviral antibodies for Zika and influenza prevention, including a $2.9 million award from Wellcome and a $749,000 contract award supported by federal funds from the Biomedical Advanced Research and Development Authority (BARDA), as part of the Flexible and Strategic Therapeutics (FASTx) Program. The awards will boost the potential of RenBio's proprietary MYO Technology platform to deliver next-generation DNA medicines for infectious disease prevention.
Company Information
Company
RenBio
Location
New York, New York, United States
About
RenBio is a privately held, preclinical biotechnology company leveraging its novel, proprietary MYO (Make Your Own) Technology™ platform to deliver next-generation antibody and protein medicines in the form of DNA therapeutics.
New YorkBiotechnologyHealth CareTherapeutics